In the ALICE study (a phase 2b trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in patients with metastatic TNBC), there was no evidence of an association between PD-L1 status and PFS or between TMB and PFS among patients receiving atezolizumab plus chemotherapy; however, in exploratory analyses, there was evidence of greater PFS benefit among patients with an above-median tumor inflammation signature19. The gene discussed is CD274; the disease is neoplasm.